CIK 0000812796 · Non-accelerated filer<br>Smaller reporting company
SOLIGENIX, INC.
Sign in to watch- Ticker
- SNGX
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 411505029
- Phone
- 609-538-8200
- Business address
- 29 EMMONS DRIVE, SUITE B-10, PRINCETON, NJ, 08540
- Former names
- SOLIGENIX, INC., DOR BIOPHARMA INC, ENDOREX CORP, IMMUNOTHERAPEUTICS INC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-10-12 | SCHABER CHRISTOPHER J CHAIRMAN, CEO AND PRESIDENT | Returned to the company · Stock Option (Right to Buy) | −250 | 0 | ||
| 2026-10-12 | SCHABER CHRISTOPHER J CHAIRMAN, CEO AND PRESIDENT | Returned to the company · Stock Option (Right to Buy) | −250 | 0 | ||
| 2026-10-12 | SCHABER CHRISTOPHER J CHAIRMAN, CEO AND PRESIDENT | Returned to the company · Stock Option (Right to Buy) | −250 | 0 | ||
| 2026-10-12 | SCHABER CHRISTOPHER J CHAIRMAN, CEO AND PRESIDENT | Returned to the company · Stock Option (Right to Buy) | −250 | 0 | ||
| 2026-10-12 | SCHABER CHRISTOPHER J CHAIRMAN, CEO AND PRESIDENT | Returned to the company · Stock Option (Right to Buy) | −52 | 0 | ||
| 2026-10-12 | SCHABER CHRISTOPHER J CHAIRMAN, CEO AND PRESIDENT | Returned to the company · Stock Option (Right to Buy) | −197 | 0 | ||
| 2026-10-12 | SCHABER CHRISTOPHER J CHAIRMAN, CEO AND PRESIDENT | Returned to the company · Stock Option (Right to Buy) | −583 | 0 | ||
| 2026-09-17 | Parks Diane L. Director | Grant or award · Stock Option (Right to Buy) | +78,947 | 78,947 | ||
| 2026-09-17 | ZELDIS JEROME B Director | Grant or award · Stock Option (Right to Buy) | +78,947 | 78,947 | ||
| 2026-09-17 | RUBIN ROBERT J. Director | Grant or award · Stock Option (Right to Buy) | +78,947 | 78,947 | ||
| 2026-09-17 | LAPOINTE ANTHONY GREGG Director | Grant or award · Stock Option (Right to Buy) | +78,947 | 78,947 | ||
| 2025-12-11 | Guarino Jonathan L. CFO | Grant or award · Option (Right to Buy) | +100,000 | 100,000 | ||
| 2025-12-11 | Donini Oreola CSO | Grant or award · Option (Right to Buy) | +100,000 | 100,000 | ||
| 2025-12-11 | Straube Richard CMO (Consulting) | Grant or award · Option (Right to Buy) | +10,000 | 10,000 | ||
| 2025-12-11 | SCHABER CHRISTOPHER J CHAIRMAN, CEO AND PRESIDENT | Grant or award · Option (Right to Buy) | +200,000 | 200,000 | ||
| 2025-10-02 | SCHABER CHRISTOPHER J CHAIRMAN, CEO AND PRESIDENT | Purchase | +15,132 | $1.32 | $20K | 15,511 |
| 2025-06-20 | LAPOINTE ANTHONY GREGG Director | Grant or award · Stock Option (Right to Buy) | +17,647 | 17,647 | ||
| 2025-06-20 | ZELDIS JEROME B Director | Grant or award · Stock Option (Right to Buy) | +17,647 | 17,647 | ||
| 2025-06-20 | RUBIN ROBERT J. Director | Grant or award · Stock Option (Right to Buy) | +17,647 | 17,647 | ||
| 2025-06-20 | Parks Diane L. Director | Grant or award · Stock Option (Right to Buy) | +17,647 | 17,647 |
Page 3 of 8 · 141 trades